Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chemotherapy

Cisplatin combinations in cervical cancer—which is best?

Nature Reviews Clinical Oncology volume 7, pages 74–75 (2010)Cite this article

Subjects

We reviewed the results of the Gynecological Oncology Group 204 (GOG-204) randomized phase III trial, which investigated four cisplatin combination chemotherapy regimens for the treatment of patients with recurrent or metastatic cervical carcinoma. As the overall survival was similar between all arms, treatment recommendations need to be tailored based on toxic effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jemal, A. et al. Cancer Statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

    Article  Google Scholar 

  2. Thigpen, T., Shingleton, H., Homesley, H., Lagasse, L. & Blessing, J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 48, 899–903 (1981).

    Article  CAS  Google Scholar 

  3. Monk, B. J. et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 27, 4649–4655 (2009).

    Article  CAS  Google Scholar 

  4. Robati, M., Holtz, D. & Dunton, C. J. A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther. Clin. Risk Manag. 4, 213–218 (2008).

    Article  CAS  Google Scholar 

  5. Long, H. J. 3rd et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 23, 4626–4633 (2005).

    Article  CAS  Google Scholar 

  6. Moore, D. H. et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J. Clin. Oncol. 22, 3113–3119 (2004).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology Lankenau Hospital, Lankenau Institute for Medical Research, Wynnewood, 19096, PA, USA

    David O. Holtz & Charles J. Dunton

Authors
  1. David O. Holtz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles J. Dunton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles J. Dunton.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holtz, D., Dunton, C. Cisplatin combinations in cervical cancer—which is best?. Nat Rev Clin Oncol 7, 74–75 (2010). https://doi.org/10.1038/nrclinonc.2009.220

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.220

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing